PDCD1 and neoplasm: Considering the immunosuppressive effect of GSPT1, the combination of GSPT1 degraders and immunotherapy, including PD‐1 inhibitors, may inhibit tumor growth, activate immune attacks, disrupt immune escape, and enhance anti‐cancer efficacy.